Tezosentan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tezosentan
Tezosentan.png
Systematic (IUPAC) name
N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide
Clinical data
Legal status ?
Identifiers
CAS number  YesY
ATC code None
PubChem CID 151174
ChemSpider 133242 YesY
UNII 64J9J55263 YesY
ChEMBL CHEMBL61780 YesY
Chemical data
Formula C27H27N9O6S 
Mol. mass 605.624
 YesY (what is this?)  (verify)

Tezosentan is a non-selective ETA and ETB receptor antagonist.[1] It acts as a vasodilator and was designed as a therapy for patients with acute heart failure. Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.[2]

References[edit]

  1. ^ Urbanowicz, W; Sogni, P, Moreau, R, Tazi, K A, Barriere, E, Poirel, O, Martin, A, Guimont, M C, Cazals-Hatem, D, Lebrec, D (2004). "Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats". Gut (BMJ Publishing Group Ltd & British Society of Gastroenterology) 53 (12): 1844–1849. doi:10.1136/gut.2003.036517. PMC 1774327. PMID 15542526. 
  2. ^ "Tezosentan does not appear to improve symptoms for patients with acute heart failure". Medical Studies/Trials. news-medical.net. 7 Nov 2007. Retrieved 2007-11-24.